Could a CF drug help people with a different lung disease?

NCT ID NCT05743946

Completed Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether Trikafta, a drug already approved for cystic fibrosis, can help people with non-cystic fibrosis bronchiectasis (NCFBE). Thirty-two adults took the medication for 28 days. Researchers measured lung function, quality of life, and weight, and also looked at how cells respond to the drug in the lab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trikafta (elexacaftor, tezacaftor, ivacaftor)
What this could lead to: If it works, this could point toward a new treatment option for people with non-cystic fibrosis bronchiectasis who have certain CFTR mutations.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drug is already approved for cystic fibrosis, but its benefits for this different condition are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-CYSTIC FIBROSIS BRONCHIECTASIS

Contacts and locations

Locations

The Emory Clinic

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.